1.19 USD
-0.06 (-4.8%)
At close: Jan 30, 2026
1.19 USD
0 (0%)
After Hours: 1/30/2026, 8:03:54 PM
We assign a fundamental rating of 1 out of 10 to MDCX. MDCX was compared to 525 industry peers in the Biotechnology industry. MDCX has a bad profitability rating. Also its financial health evaluation is rather negative. MDCX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year MDCX has reported negative net income.
- In the past 5 years MDCX always reported negative net income.
- In the past 5 years MDCX always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of MDCX (-195.00%) is worse than 87.62% of its industry peers.
- The Return On Equity of MDCX (-319.45%) is worse than 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -195% | ||
| ROE | -319.45% | ||
| ROIC | N/A |
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for MDCX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, MDCX has more shares outstanding
- Compared to 5 years ago, MDCX has more shares outstanding
- There is no outstanding debt for MDCX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -5.46, we must say that MDCX is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -5.46, MDCX is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
- MDCX has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
- MDCX has a Debt to Equity ratio of 0.07. This is in the lower half of the industry: MDCX underperforms 60.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.46 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- MDCX has a Current Ratio of 2.73. This indicates that MDCX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.73, MDCX is doing worse than 67.62% of the companies in the same industry.
- A Quick Ratio of 2.73 indicates that MDCX has no problem at all paying its short term obligations.
- MDCX has a Quick ratio of 2.73. This is in the lower half of the industry: MDCX underperforms 65.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.73 |
3. Growth
3.1 Past
- MDCX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.89%, which is quite impressive.
EPS 1Y (TTM)27.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, MDCX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.48% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.41%
EPS Next 2Y26.56%
EPS Next 3Y16.13%
EPS Next 5Y20.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- MDCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDCX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- MDCX's earnings are expected to grow with 16.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.56%
EPS Next 3Y16.13%
5. Dividend
5.1 Amount
- No dividends for MDCX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MEDICUS PHARMA LTD / MDCX FAQ
Can you provide the ChartMill fundamental rating for MEDICUS PHARMA LTD?
ChartMill assigns a fundamental rating of 1 / 10 to MDCX.
What is the valuation status for MDCX stock?
ChartMill assigns a valuation rating of 0 / 10 to MEDICUS PHARMA LTD (MDCX). This can be considered as Overvalued.
What is the profitability of MDCX stock?
MEDICUS PHARMA LTD (MDCX) has a profitability rating of 0 / 10.
Can you provide the financial health for MDCX stock?
The financial health rating of MEDICUS PHARMA LTD (MDCX) is 3 / 10.
What is the earnings growth outlook for MEDICUS PHARMA LTD?
The Earnings per Share (EPS) of MEDICUS PHARMA LTD (MDCX) is expected to grow by 4.41% in the next year.